Preclinical Imaging Scientist (Temporary) at ARTBIO

Summary We are seeking a motivated and detail-oriented preclinical imaging scientist to join our preclinical radiopharmaceutical development team on a temporary basis. The successful candidate will contribute to translational research programs involving small-animal nuclear imaging, supporting the evaluation and characterization of novel radiopharmaceuticals. Duration: 8–12 months Start Date: January 2026 Key Responsibilities • Conduct small-animal imaging studies (PET/SPECT/CT) in accordance with approved protocols and ethical standards. • Perform animal handling, dosing (including i.V injection), anesthesia, and post-imaging procedures. • Prepare and administer radiopharmaceuticals safely under radiation protection regulations. • Collaborate with radiochemistry, pharmacology, and image analysis teams to ensure high-quality data generation and interpretation. • Maintain study records and contribute to internal reports and data summaries. • Ensure compliance with animal welfare regulations and institutional safety requirements. Essential Qualifications • Degree (MSc/PhD) in biomedical sciences, pharmacology, radiochemistry, medical physics, or a related field. • Hands-on experience with small-animal models (mice and rats), supported by certified training in laboratory animal science (FELASA Category C, CAREiN, or equivalent). • Practical experience in PET/SPECT imaging modalities, image reconstruction and quantitative image analysis. • Knowledge of radiopharmaceutical development principles and in vivo imaging workflows. • Proven ability to work both independently and collaboratively in a multidisciplinary environment. About Us ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn and Twitter.  As an emerging, global biotech with locations in Boston, Massachusetts, Basel, Switzerland, London, England and Oslo, Norway, we take advantage of diverse scientific depth and insights which makes ARTBIO a unique place to work.  We are driven by a desire to do better for cancer patients, lowering the burden of toleration and safety while at the same time raising the bar on clinical efficacy and duration.  EEO Statement ARTBIO is proud to be an equal opportunity workplace and is an affirmative action employer. We are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status. If you have a disability or special need that requires accommodation, please let us know. ARTBIO does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between ARTBIO and the agency. ARTBIO will not pay any fees related to unsolicited resumes.